welcome to Treatment strategy of Chinese thrombosis disease!

Home > Exchange > Academic Journal

The benefits of thrombolytic therapy in patients with acute ischemic stroke who received antiplatelet therapy were greater than risk


According to Stroke Volume 41, Issue 2: February 1, 2010, a study in Germany using the data from the Stroke Thrombolytic Safety International Stroke Thrombolysis (SITS-ISTR) study found that in the acute absence of antiplatelet therapy In patients with hemodialysis, 1.4% had symptomatic systolic hemorrhage (SICH), but none of the patients with subgroups of antiplatelet therapy and SICH mortality or adverse function were significantly increased. The clinical benefit of thrombolytic therapy is greater than the risk of SICH, and antiplatelet therapy should not be contraindicated as thrombolytic therapy.

Return List